Evidence for Cytochrome P4503A4 Involvement in Their Major Metabolic Pathways
Abstract
The mutual inhibition between quinine and etoposide with their major metabolic pathways (i.e. quinine 3-hydroxylation and etoposide 3′-demethylation) was examined in vitro by human liver microsomes. Etoposide inhibited quinine 3-hydroxylation in a concentration-dependent manner with a mean IC50of 65 μM. The mean maximum inhibition by etoposide (100 μM) of quinine 3-hydroxylation was about 60%. Similarly, etoposide 3′-demethylation was inhibited by quinine in a concentration-related manner with a mean IC50 value of 90 μM. The mean maximum inhibition by quinine (100 M) of etoposide 3′-demethylation was about 52%. An excellent correlation (r = 0.947, p < 0.01) between quinine 3-hydroxylase and etoposide 3′-demethylase activities in six different human liver microsomes was observed. Two inhibitors of CYP3A4, ketoconazole (1 μM) and troleandomycin (100 μM), inhibited quinine 3-hydroxylation by about 90% and 80%, and etoposide 3′-demethylation by about 75% and 65%, respectively. We conclude that quinine and etoposide mutually inhibit the metabolism of each other, consistent with the previous finding that CYP3A4 catalyzes the metabolism of both substrates.
Footnotes
-
Send reprint requests to: Takashi Ishizaki, M.D., Ph.D., Department of Clinical Pharmacology, Research Institute, International Medical Center of Japan, 1–21-2 Toyama, Shinjuku-ku, Tokyo 162, Japan.
-
This study was supported by a grant-in-aid from the Ministry of Human Health and Walfare, Tokyo, Japan.
- Received August 7, 1997.
- Accepted November 11, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|